Suppr超能文献

可切除胃癌中胞浆组织蛋白酶D含量的预后价值

Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer.

作者信息

Manuel Del Casar José, Vizoso Francisco José, Abdel-Laa Omar, Sanz Lourdes, Martín Aranzazu, Daniela Corte María, Bongera Miguel, García Muñiz José Luis, Fueyo Antonio

机构信息

Department of Surgery, Hospital de Jove, Gijón, Spain.

出版信息

J Surg Oncol. 2004 Apr 1;86(1):16-21. doi: 10.1002/jso.20041.

Abstract

BACKGROUND AND AIMS

Cathepsin D (Cath-D) is an aspartyl protease involved in protein catabolism and tissue remodelling. In the present article, we evaluate the tumor content of Cath-D in resectable gastric carcinomas and its relation with clinical and pathological parameters, as well as its prognostic significance.

METHOD

This prospective study included a series of 60 patients with primary gastric adenocarcinoma, who first underwent a complete surgical resection of their tumors and then were evaluated for disease recurrence and survival status during a mean follow-up period of 41.5 months. Cath D was measured in cytosolic samples using an immune-radiometric assay which determined the total amount of Cath-D (52K, 48K, and 34K).

RESULTS

The tumor content of Cath-D ranged from 4 to 247 pmol/mg protein and from 6.4 to 97.7 pmol/mg protein in adjacent non-neoplastic mucosa samples. Cytosolic Cath-D levels were significantly higher in neoplastic tissues (P < 0.001). Statistical analysis also demonstrated that younger patients showed lower Cath-D tumor levels than older ones. Likewise, patients with lower tumor levels of Cath-D had better survival than those with intermediate or high Cath-D tumor content (P = 0.002). This finding showed an independent prognostic value on survival (P = 0.02).

CONCLUSIONS

The present study demonstrates the presence of higher Cath-D content in gastric carcinomas than in adjacent non-neoplastic mucosa, and that high intratumor Cath-D levels identify a subgroup of resectable gastric cancer patients with a high probability of relapse as well as worse survival.

摘要

背景与目的

组织蛋白酶D(Cath-D)是一种参与蛋白质分解代谢和组织重塑的天冬氨酸蛋白酶。在本文中,我们评估了可切除胃癌中Cath-D的肿瘤含量及其与临床和病理参数的关系,以及其预后意义。

方法

这项前瞻性研究纳入了60例原发性胃腺癌患者,这些患者首先接受了肿瘤的完整手术切除,然后在平均41.5个月的随访期内评估疾病复发和生存状况。使用免疫放射分析测定细胞溶质样品中的Cath D,该分析确定了Cath-D(52K、48K和34K)的总量。

结果

Cath-D的肿瘤含量在4至247 pmol/mg蛋白质之间,相邻非肿瘤黏膜样品中的含量在6.4至97.7 pmol/mg蛋白质之间。肿瘤组织中的细胞溶质Cath-D水平显著更高(P < 0.001)。统计分析还表明,年轻患者的Cath-D肿瘤水平低于老年患者。同样,Cath-D肿瘤水平较低的患者比Cath-D肿瘤含量中等或较高的患者生存更好(P = 0.002)。这一发现显示了对生存的独立预后价值(P = 0.02)。

结论

本研究表明,胃癌中的Cath-D含量高于相邻的非肿瘤黏膜,并且肿瘤内Cath-D水平高可识别出一组可切除胃癌患者,这些患者复发概率高且生存较差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验